An 8% increase in quarterly revenues wasn’t enough to restore ADAC Laboratories to profitability. The nuclear medicine and healthcare information systems vendor reported revenues of $75.6 million for the quarter (end-July 4), compared with revenues
An 8% increase in quarterly revenues wasnt enough to restore ADAC Laboratories to profitability. The nuclear medicine and healthcare information systems vendor reported revenues of $75.6 million for the quarter (end-July 4), compared with revenues of $69.8 million for the third quarter of 1998. Net loss for the quarter, however, was $5.4 million, compared with net income of $3.4 million in the same period a year ago. The unsatisfactory earnings report was the latest in a series of disappointments for the Milpitas, CA-based firm, which has been beset by a decline in nuclear medicine market share and an earnings restatement that took place in late 1998 (SCAN 8/4/99).
These financial results put ADAC out of compliance with its $75 million revolving credit facility, and the company is negotiating an amendment to the facility that will include a waiver of its third-quarter default as well as modified financial covenants that better reflect the companys current financial performance. As of Aug. 24, ADAC stock was trading at $6.31; slightly above its 52-week low of $5.75 but well below its high of $22.75. Revenues are expected to rise again in the fourth quarter, according to Andrew Eckert, ADAC chairman and CEO.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.